DelRicht Research was selected as a participating site network for a Phase 3 Pneumococcal Vaccine trial enrolling healthy adults, 50+ years old, with most recent pneumococcal vaccines completed more than a year prior to the start of the study.

From challenges including eligibility recruitment, protocol eDiary compliance, and technical barriers for unfamiliar populations, DelRicht was able to deliver study startup milestones that set the pace for this competitive trial.

Navigating Complex Recruitment Barriers

Like many large, multi-site clinical vaccine trials, this pneumococcal study presented several operational and recruitment complexities that posed challenges to both enrollment and overall execution.

Vaccination Documentation: Pneumococcal vaccinations are frequently administered via retail pharmacies rather than primary care providers, resulting in fragmented electronic medical record documentation.

Proactive Compliance Monitoring: Heavy reliance on electronic diary data for symptom tracking created significant challenges in ensuring consistent compliance, preventing protocol deviations from missed entries, and technical support for digital tools for unfamiliar patient populations.

Targeted Strategies to Drive Recruitment and Compliance

DelRicht addressed these challenges through a combination of operational discipline, community engagement, and tailored recruitment strategies:

Optimized Recruitment: DelRicht leveraged our existing referral networks and cross-referenced external immunization logs. We reduced screen failures by refining intake to capture key exclusion criteria upfront, pre-identifying pneumococcal vaccine recipients through database and medical record review, and cross-verifying vaccination history. Multi-channel outreach and centralized call center guides patients from interest to enrollment. With ~10 leads required per qualified pre-screen, our team scaled capacity to be able to contact a high volume of patients, all within 10 minutes of indicating interest, driving high conversion to meet enrollment goals.

Facilitated eDiary Compliance: Enhanced diary compliance through a comprehensive approach combining proactive daily monitoring, real-time reminders and automated alerts, 24/7 patient support for troubleshooting, and dedicated coordinators for immediate follow up for missed entries, ensuring high data quality.

High-Quality Data, and Network-Wide Impact

Through these combined efforts, DelRicht Research enrolled 67 patients across three sites in just one month. Driven by same-day activation at all three locations, Dr. Kymberly Moyer’s site in Tennessee led the study by achieving First Subject Enrolled studywide.

Dr. Kymberly Moyer at Magnolia Family Medicine | Hendersonville, TN

Dr. Luke Van Kirk at Command Family Medicine | Springfield, MO

Dr. Patrick Dennis at Touro Medical Center | New Orleans, LA

DelRicht Research’s Managing Partner, Tyler Hastings weighed in:

“Securing First Subject Recruited studywide milestone in a competitive, U.S.Phase 3 vaccine trial is a testament to top-tier site readiness,” said Tyler Hastings, Managing Partner at DelRicht Research. “Speed and enrollment momentum are everything in late-stage vaccine development, especially when evaluating a critical pneumococcal candidate. Our team’s leadership and operational precision are exactly why sponsors trust our network to execute protocols efficiently.”

While recruitment barriers and operational bottlenecks frequently delay similar vaccine trials, DelRicht’s embedded research model bypasses these hurdles, delivering consistent, high-speed performance across all locations without compromising data integrity.

What This Means for Sponsors and CROs

This study reinforces key advantages of working with a fully aligned site network. Rapid start-up timelines are achievable with centralized coordination and experienced teams. Recruitment barriers, whether behavioral, clinical, or logistical, can be mitigated with tailored, site-level strategies. Complex populations require intentional expertise and education, not one-size-fits-all approaches.

Partner With Us

From start-up to quality data capture, DelRicht Research delivers the infrastructure, experience, and adaptability required for complex vaccine protocols. If you’re planning an upcoming vaccine study, our team is ready to help you accelerate timelines, improve enrollment outcomes, and maintain data quality from start to finish.

Learn more at www.DelRichtResearch.com or connect with us to discuss your next vaccine trial.